Welcome to our dedicated page for Sintx Technologies SEC filings (Ticker: SINT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to SINTX Technologies, Inc. (NASDAQ: SINT) SEC filings, offering detailed insight into the company’s silicon nitride biomaterials business, capital structure, and governance. Filings are sourced in real time from the SEC’s EDGAR system and organized so investors can quickly locate key documents.
Through SINTX’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q, readers can review narrative business descriptions, risk factors, financial statements, and management’s discussion of its advanced ceramics and medical device operations. These reports also describe the company’s focus on infection‑resistant silicon nitride devices, polymer composites, and antipathogenic fabric technologies, as well as its U.S.‑based manufacturing footprint and patent portfolio.
Current reports on Form 8‑K document material events such as FDA 510(k) submissions and clearances, asset purchase agreements, at‑the‑market offering arrangements, warrant inducement transactions, and other financing activities. For example, recent 8‑K filings describe an ATM Offering Agreement with H.C. Wainwright & Co., an inducement agreement related to warrant exercises, and an asset purchase agreement for foot and ankle implant assets.
The DEF 14A proxy statement provides information on board elections, auditor ratification, executive compensation proposals, and equity incentive plans, along with details about the annual meeting of stockholders. Together, these filings help investors understand SINTX’s governance structure and shareholder matters.
Stock Titan’s platform enhances these documents with AI‑powered summaries that highlight important sections, such as business updates, capital‑raising terms, and key risk disclosures, reducing the time needed to interpret lengthy filings. Users can also review Form 4 and related insider transaction filings to see how directors and officers transact in SINTX common stock over time.
By using this page, investors can efficiently navigate SINTX’s 10‑K, 10‑Q, 8‑K, proxy, and insider filings, while AI‑generated insights point to the sections most relevant to the company’s silicon nitride technology platform and financial condition.
Director Mark Lewis Anderson of Sintx Technologies has reported a significant insider purchase of company shares. On June 18, 2025, Anderson acquired 10,000 shares of Common Stock at a price of $3.30 per share, representing a total investment of $33,000.
Following this transaction, Anderson's direct ownership increased to 15,000 shares of Sintx Technologies common stock. The purchase was executed as a standard market transaction and was reported through Form 4 filed with the SEC on June 28, 2025.
This insider buying activity by a board member could be viewed as a positive signal about the company's prospects, as directors often purchase shares when they believe the stock is undervalued or expect positive developments. The transaction was authorized through power of attorney by Kevin Ontiveros.